Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Neoplasms 1Endometrial Neoplasms 1Carcinoma 1

Interventions

Paclitaxel 6pembrolizumab 3Cisplatin 3Carboplatin 3Biopsy 3adavosertib 2Trastuzumab 2Magnetic Resonance Spectroscopy 2Fulvestrant 2Doxorubicin 2ulixertinib 1tucatinib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1selinexor 1sapanisertib 1sacituzumab govitecan 1relugolix 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1niraparib 1larotrectinib 1ipatasertib 1erdafitinib 1dostarlimab 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Neoplasms × VMBP protocol × 1 year × Clear all
NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

University of Alabama at Birmingham

Phase 1/2 Recruiting
37 enrolled
Gynecologic

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡